GnRH antagonist
Cetrorelix
Answer
Cetrorelix is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. No trial states a phase. It has 140 registered trials, 14 of them running. Brand names on the FDA label register: Cetrorelix Acetate and Cetrotide.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov, read 2026-10-03
Not medical, legal or regulatory advice.
140 trials by status
Trial registerClinicalTrials.gov · read 2026-10-03 · 8 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 65 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Cetrorelix changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 140 trials
| NCT07732348 | Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: not yet recruiting participants · register updated 2026-09-30 |
|---|---|
| NCT07836400 | Half-dose vs Conventional-dose Cetrorelix in ICSI Cycles not yet recruiting participants · register updated 2026-09-23 |
| NCT07340827 | A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH D currently recruiting participants · register updated 2026-09-08 |
| NCT07736261 | Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI not yet recruiting participants · register updated 2026-07-30 |
| NCT06572930 | Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation currently recruiting participants · register updated 2026-06-25 |
| NCT06212102 | Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation currently recruiting participants · register updated 2026-05-04 |
| NCT05951400 | Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI completed · register updated 2026-04-15 |
| NCT02892942 | NATural Ovarian Stimulation completed · register updated 2026-04-03 |
| NCT02890082 | Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer running, but no longer enrolling · register updated 2026-03-31 |
| NCT04719000 | PErsonalized Addition of Recombinant LH in Ovarian Stimulation currently recruiting participants · register updated 2026-03-30 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.